Show simple item record

dc.contributor.authorAgar, Meera Ruth
dc.contributor.authorTo, Timothy H M
dc.contributor.authorPlummer, John Lewis
dc.contributor.authorAbernethy, Amy Pickar
dc.contributor.authorCurrow, David Christopher
dc.date.accessioned2013-08-28T03:20:26Z
dc.date.available2013-08-28T03:20:26Z
dc.date.issued2010-07-02
dc.identifier.citationAgar, M.R., To, T.H.M., Plummer, J., Abernethy, A.P. and Currow, D.C., 2010. Anti-cholinergic load, health care utilization, and survival in people with advanced cancer: a pilot study. Journal of Palliative Medicine, 13(6), 745-752.en
dc.identifier.issn1096-6218
dc.identifier.urihttp://hdl.handle.net/2328/27013
dc.description.abstractIntroduction: Anti-cholinergic medications have been associated with increased risks of cognitive impairment, premature mortality and increased risk of hospitalisation. Anti-cholinergic load associated with medication increases as death approaches in those with advanced cancer, yet little is known about associated adverse outcomes in this setting. Methods: A substudy of 112 participants in a randomised control trial who had cancer and an Australia modified Karnofsky Performance Scale (AKPS) score (AKPS) of 60 or above, explored survival and health service utilisation; with anti-cholinergic load calculated using the Clinician Rated Anti-cholinergic Scale (modified version) longitudinally to death. A standardised starting point for prospectively calculating survival was an AKPS of 60 or above. Results: Baseline entry to the sub-study was a mean 62 ± 81 days (median 37, range 1–588) days before death (survival), with mean of 4.8 (median 3, SD 4.18, range 1 – 24) study assessments in this time period. Participants spent 22% of time as an inpatient. There was no significant association between anti-cholinergic score and time spent as an inpatient (adjusted for survival time) (p = 0.94); or survival time. Discussion: No association between anti-cholinergic load and survival or time spent as an inpatient was seen. Future studies need to include cognitively impaired populations where the risks of symptomatic deterioration may be more substantial.en
dc.language.isoen
dc.publisherMary Ann Liebert, Inc.en
dc.subjectPalliative care
dc.titleAnti-cholinergic load, health care utilization, and survival in people with advanced cancer: a pilot studyen
dc.typeArticleen
dc.identifier.doihttps://doi.org/10.1089/jpm.2009.0365en
dc.rights.holder(C) Mary Ann Liebert, Inc. 2010en
dc.rights.licenseIn Copyright
local.contributor.authorOrcidLookupCurrow, David Christopher: https://orcid.org/0000-0003-1988-1250en_US
local.contributor.authorOrcidLookupTo, Timothy H M: https://orcid.org/0000-0003-0025-6543


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record